JCJavier Ugarte Chicote

Javier Ugarte Chicote

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Javier Ugarte Chicote has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Carmen Aguilar

    Grup de Recerca GEMMAIR (AGAUR) - Medicina Aplicada (URV). Departament de Medicina i Cirurgia. Universitat Rovira i Virgili (URV), Institut d'Investigació Sanitària Pere Virgili (IISPV). Mallafré Guasch, 4 43007, Tarragona, Spain

    4 shared publications
  • Teresa Auguet

    Grup de Recerca GEMMAIR (AGAUR)-Medicina Aplicada (URV), Departament de Medicina i Cirurgia, Universitat Rovira i Virgili (URV), Institut d’Investigació Sanitària Pere Virgili (IISPV), Mallafré Guasch, 4, 43007 Tarragona, Spain

    4 shared publications
  • David Riesco

    Grup de Recerca GEMMAIR (AGAUR)—Medicina Aplicada (URV), Departament de Medicina i Cirurgia, Institut d’Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili (URV), Mallafré Guasch 4, 43007 Tarragona, Spain

    3 shared publications
  • Fàtima Sabench

    Grup de Recerca en Cirurgia del IISPV, Universitat Rovira i Virgili, 43204 Reus, Spain

    3 shared publications
  • Helena Clavero-Mestres

    Grup de Recerca GEMMAIR (AGAUR)-Medicina Aplicada (URV), Departament de Medicina i Cirurgia, Universitat Rovira i Virgili (URV), Institut d’Investigació Sanitària Pere Virgili (IISPV), Mallafré Guasch, 4, 43007 Tarragona, Spain

    3 shared publications
  • Salomé Martínez

    Grup de Recerca GEMMAIR (AGAUR)—Medicina Aplicada (URV), Departament de Medicina i Cirurgia, Institut d’Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili (URV), Mallafré Guasch 4, 43007 Tarragona, Spain

    3 shared publications

Latest Publications

  • Open Access

    sTREM2 evaluation in women with metabolic dysfunction-associated steatotic liver disease: Advancing diagnostic approaches for early MASH

    by Razieh Mahmoudian, Helena Clavero-Mestres, Elena Cristina Rusu, Vicente Arredondo-Prats, Carmen Aguilar, Javier U Chicote, Salomé Martinez, David Riesco, Èlia Bartra, Anna Trinidad Borras, et al.


  • Open Access

    Differential Expression of Lipid Metabolism Genes, CROT and ABCG1, in Obese Patients with Comorbid Depressive Disorder and Risk of MASLD

    by Joanna Michalina Jurek, Elena Cristina Rusu, Javier Camaron, Helena Clavero-Mestres, Carmen Aguilar, David Riesco, Belen Xifré, Javier U. Chicote, Salomé Martinez, Marga Vives, et al.

    Background: There is accumulating evidence supporting a bidirectional relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and depressive disorder (DD), with possible genetic factors related to hepatic lipid metabolism. Our aim was to analyse the prevalence of DD in patients with obesity at risk of MASLD, and to evaluate the hepatic expression of genes involved in lipid metabolism, in patients with DD. Methods: In 152 patients with morbid obesity who underwent bariatric surgery, medical data, blood and liver samples were collected. Liver biopsies were scored for MASLD staging were used for gene expression analysis. Results: The DD prevalence in this cohort was 29.6%, and patients with DD had a significantly higher hepatic expression of the CROT and ABCG1 genes. Moreover, patients in the MASLD group showed significantly higher relative hepatic expression of SREBP1 and ABCG1 genes compared to the normal liver group. Some anthropometric and clinical measures (BMI and DBP) were positively correlated with the expression of SREBP2, ABCG1 and CROT genes, while the expression of CPT1α was negatively correlated with age, SBP and DBP. There was a positive relationship between GGT and ALP levels and the relative expression of ABCG1 and ACC1 genes. Conclusions: In this study, individuals with morbid obesity demonstrated an elevated prevalence of DD. Moreover, hepatic genetic dysregulation of lipid metabolism may influence the interplay between MASLD and DD in patients with morbid obesity.


  • Open Access

    Differential Profiles of Gut Microbiota-Derived Metabolites of Bile Acids and Propionate as Potential Predictors of Depressive Disorder in Women with Morbid Obesity at High Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease—A Pilot Study

    by Joanna Michalina Jurek, Belen Xifré, Elena Cristina Rusu, Helena Clavero-Mestres, Razieh Mahmoudian, Carmen Aguilar, David Riesco, Javier Ugarte Chicote, Salomé Martinez, Marga Vives, et al.

    Metabolic dysfunction-associated steatotic liver disease (MASLD) is a liver condition linked to cardiometabolic diseases and mental health issues, with studies highlighting disruptions in gut microbiota activity, including bile acid (BA) metabolism. Therefore, the main aim of this exploratory analysis was to assess microbiota-derived metabolites, specifically BAs and short-chain fatty acids (SCFAs), as potential biomarkers of depressive disorder (DD) in women with morbid obesity at MASLD risk. In this pilot study, 33 females with morbid obesity who were scheduled for bariatric surgery were evaluated. Medical and clinical data were collected, and microbial metabolites from pre-surgery blood samples were analyzed. Patients were stratified according to the presence of DD. Analysis with Spearman’s rank test was used to assess correlations and logistic regression models were built to evaluate biomarkers as predictors of DD risk using both receiver operating characteristic (ROC) and precision–recall curves. In this cohort, 30.3% of females were reported to have DD, in addition to significantly elevated levels of certain BAs and SCFAs, including glycodeoxycholic acid (GDCA) and propionate, which were also correlated with some metabolic biomarkers. However, there were no differences in the incidence of MASLD or metabolic syndrome between patients with DD or without. In conclusion, microbiota-derived metabolites such as GDCA and propionate may influence DD risk in females with morbid obesity; however, their potential use as predictive biomarkers should be further investigated to confirm their role in psycho-metabolic conditions.


  • Open Access

    Identification of the Potential Molecular Mechanisms Linking RUNX1 Activity with Nonalcoholic Fatty Liver Disease, by Means of Systems Biology

    by Laia Bertran, Ailende Eigbefoh-Addeh, Marta Portillo-Carrasquer, Andrea Barrientos-Riosalido, Jessica Binetti, Carmen Aguilar, Javier Ugarte Chicote, Helena Bartra, Laura Artigas, Mireia Coma, et al.

    Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic hepatic disease; nevertheless, no definitive diagnostic method exists yet, apart from invasive liver biopsy, and nor is there a specific approved treatment. Runt-related transcription factor 1 (RUNX1) plays a major role in angiogenesis and inflammation; however, its link with NAFLD is unclear as controversial results have been reported. Thus, the objective of this work was to determine the proteins involved in the molecular mechanisms between RUNX1 and NAFLD, by means of systems biology. First, a mathematical model that simulates NAFLD pathophysiology was generated by analyzing Anaxomics databases and reviewing available scientific literature. Artificial neural networks established NAFLD pathophysiological processes functionally related to RUNX1: hepatic insulin resistance, lipotoxicity, and hepatic injury-liver fibrosis. Our study indicated that RUNX1 might have a high relationship with hepatic injury-liver fibrosis, and a medium relationship with lipotoxicity and insulin resistance motives. Additionally, we found five RUNX1-regulated proteins with a direct involvement in NAFLD motives, which were NFκB1, NFκB2, TNF, ADIPOQ, and IL-6. In conclusion, we suggested a relationship between RUNX1 and NAFLD since RUNX1 seems to regulate NAFLD molecular pathways, posing it as a potential therapeutic target of NAFLD, although more studies in this field are needed.